This guidance provides information on the provision of the third-generation smallpox vaccination JYNNEOS for the prevention of mpox disease in close contacts of mpox cases in NSW.
JYNNEOS is the preferred vaccine for post-exposure preventative vaccination (PEPV) in NSW due to its favourable safety profile and ease of administration. If indicated, PEPV should be administered as soon as possible after presumed or confirmed exposure to a person with mpox, ideally within 4 days after last exposure, although administration up to 14 days can be considered as it may attenuate disease severity.
PEPV can be given to people who are identified as high and medium risk contacts who:
For the purposes of PEPV, a single dose of 0.5mL (subcutaneous) is required for protection against contracting mpox infection and attenuating disease/symptoms. If mpox has not occurred and there is a significant ongoing risk of exposure, a second dose of JYNNEOS may be considered at least 28 days after the first dose as completion of a primary course for long-term protection.
The Australian Technical Advisory Group on Immunisation (ATAGI) recommendations have been updated to remove the age restriction; people of all ages who are at risk of exposure to mpox are recommended to receive mpox vaccination. Vaccination of child contacts can occur after a discussion with the treating clinician of the risks/benefits.
Contacts presenting for PEPV who have received a single dose of JYNNEOS vaccine should be offered a second dose if at least 28 days has passed since their first dose.
Contacts who have received two doses of the JYNNEOS vaccine do not require PEPV after being exposed to mpox. Currently, the Australian Technical Advisory Group on Immunisation does not recommend booster doses of the mpox vaccine for people fully vaccinated with 2 doses, including those who are severely immunocompromised.
Recovery from infection (regardless of clade) likely confers protection from either clade of mpox. It is possible for individuals who have recovered from mpox to experience a reinfection, but this is thought to be rare, and the second infection is generally milder than the initial infection. Because of this, people who have recovered from mpox are not recommended to receive JYNNEOS vaccine doses at this time.
Vaccination given after the onset of signs or symptoms of mpox, after a diagnosis of mpox, or is not recommended or expected to provide benefit.
Vaccine should only be ordered from the State Vaccine Centre when at-risk contacts are not able to access vaccine from an existing provider.
The process of ordering and administration of vaccine should be as follows:
On the next business day, the PHU should arrange with the pharmacy to transport the remaining vaccine in its original packaging to a local authorised site, most commonly a sexual health clinic. Records of distribution must be kept in line with the state-wide protocol for JYNNEOS vaccine consent, supply and administration in NSW.